Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions
Cleerly is aware of the lawsuit filed by Heartflow. We are confident in our extensive and well-established intellectual property portfolio and the originality of our technology.
Cleerly has published landmark clinical science that has redefined how cardiovascular disease is understood and treated, which has formed the basis of our novel technologies that provide physicians with actionable insights into their patients’ heart health.
Cleerly was founded on a mission to create a world without heart attacks, and we have never been more focused in our mission and committed to the patients and physicians who count on us.
For any questions, please reach out to press@cleerlyhealth.com
Cleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions
Cleerly will demonstrate its FDA-cleared heart image analyses using mobile scanners in collaboration with Corazon Imaging and Philips
December 4, 2024 (DENVER) – TodayCleerly, a leader in advanced cardiovascular imaging, announced the successful closure of its Series C...
Join Cleerly Leadership for Live Demonstrations on Advanced Imaging Solutions for Personalized Heart Disease Care